The replacement diabetes drug to Takeda blockbuster drug Actos could face an eight month delay, as the Food and Drug Administration debate approval. The FDA will respond to an application by Takeda Pharmaceutical Co. to sell Alogliptin.
The experimental medication will be decided on by late June 2009, with the final deadline of October 27th. Takeda, who are based in Osaka, Japa, released a statement detailing the decision. Actos, which is the best selling diabetes drug in the world, will lose patent protection in 2011 and may then experience a decline in sales .
A spokeswoman for Takeda, Ayako Iwamuro, was reported in the diabetes news as commenting: “It’s an FDA matter. They didn’t ask us for any additional data.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…